Robert Hradil/Getty Images News
- The World Health Organization has recommended Gilead Sciences' (NASDAQ:GILD) recently FDA-approved twice yearly HIV pre-exposure prophylaxis (PrEP) treatment Yeztugo (lenacapavir).
- "With just two doses per year, [Yeztugo] is a transformative step forward in protecting people at risk of HIV – particularly those who face